• Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
• Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
• Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors. Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to obstacles like gut disorders and stomach acid and liver biotransformation. Although Lexaria is focused on pharmaceutical bioavailability, it’s interesting to note that bioavailability even plays a role in nutrition. While macronutrients (carbs and fat) offer higher levels of bioavailability – micronutrients, commonly sold as supplements (vitamins, minerals, flavonoids, and carotenoids), can be harder for the body to absorb. Studies show that not all the nutrients we eat enter the bloodstream after entering the digestive tract. Some factors that affect bioavailability include where the food is grown or made, when it was harvested, how it was prepared, the foods you eat with it, and highly individualized physiological traits that affect how your body processes that food. With studies showing that around 40% of available drugs are poorly bioavailable (https://ibn.fm/xy86j), the determined factors that affect drug bioavailability include:

• The size of the drug’s molecule
• The type of drug administered
• The amount of food eaten
• The time of day the drug is taken

Understanding the bioavailability of a drug is crucial for clinicians looking for appropriate routes of administration and schedule for drug delivery. Lexaria is investigating its DehydraTECH technology for increased bioavailability of APIs with epilepsy, high blood pressure, dementia, diabetes, and more. The global pharmaceutical drug delivery market is projected to reach $2.21 billion by 2026, growing with a CAGR of 5.9% from a value of $1.66 billion in 2021. Growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements, which include new product launches (https://ibn.fm/cJq4l). Animal studies have also demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, Lexaria’s technology has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes. The company’s recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. The findings from the study further support Lexaria’s efforts and clinical trials, which are currently being explored for other indications, including hypertension, dementia, and diabetes. The indications explored by Lexaria are chosen due to their current underserved medical needs, as DehydraTECH helps enhance bioavailability of substances for treatment. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Claude Bejet, a long-time precious metals investor and author of the Swiss Gold Letter, was interviewed on the sidelines of the recent Mines and Money Conference in London
• During his interview, Bejet commented on his optimism in regards to the precious metals complex as well as the considerable value held by junior mining companies
• Eloro Resources possesses a 100% option agreement on the Iska Iska deposit, a major polymetallic epithermal porphyry complex covering over 900 hectares of land
• The company is due to publish their initial assessment of Iska iska’s resource potential by March 2023, a process which Eloro are carrying out with mining consultancy, Micon International

“We’ve been through hell.” That was Claude Bejet’s succinct summary of the precious metals market and gold over the past two years. A Covid-linked downturn in 2020 was subsequently followed by an inflation-driven bear market across financial assets in 2022; although gold has historically been perceived as an inflation hedge, a rapidly appreciating US dollar – which rose by over 12% in 2022, hitting a two-decade high in September – marred what could have heralded a banner year for precious metals. However now and on the sidelines of the Mines & Money London conference, Claude Bejet expressed his belief that the worst could now be over; in an interview with industry newswire Kitco Mining, Bejet expressed his renewed optimism on the precious metals complex and commented on his optimism on the overlooked potential of listed mining companies (https://ibn.fm/WJC4x).

Marc Bristow, the CEO of Barrick Gold Corp, told investors during his keynote speech at the conference that the future of mining no longer lay in the traditional, over-explored jurisdictions of prior years. Rather, the big opportunities over the next decade would come from traditionally overlooked jurisdictions with Bolivia ranking chief amongst these. Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec has epitomised the potential success that could be derived from a focus in less traditional jurisdictions. Between 2020 and 2021, Eloro Resources witnessed its stock price rise by over 2,900% – a remarkable outcome resulting from the company’s world class silver-tin discovery with the near inexhaustible Cerro Rico mining belt (https://ibn.fm/FS9GO).

The mines around the Cerro Rico region have gained a near legendary reputation within precious mining circles, having produced approximately 2.1-3 billion ounces of silver over the past 500 years – making it the single richest source of silver in human history. In fact and between the 16^th and 18^th century, 80% of the world’s silver supply originated from the Cerro Rico region. In early 2020, Eloro Resources sought to capitalize on the region’s potential, optioning the Iska Iska project, a 484 square kilometre undeveloped mining tract within the Potosi region – a mere 180 kilometers south of the prolific Cerro Rico deposit.

Since commencing the inaugural drill program at the Iska Iska site in September 2020, Eloro Resources has drilled over 120 holes and 85,000 meters within the property, however it was their initial discoveries in late 2020 that convinced the company of the site’s relative potential. Between November 2020 and January 2021, the company found that its initial holes – most of which were between 250 and 300 meters in length, were delivering bulk tonnage of 150 silver grams equivalent per ton – a level of silver concentration which has been found to be economically viable in the past.

According to Bejet, the current equity market downturn could make for propitious timing for investors seeking to increase their allocation towards listed miners which may have been otherwise been overlooked by the market, with Eloro Resources chief amongst these. Boasting one of the most potentially significant silver and tin deposits within the Cerro Rico region and having recently looked to expand their addressable deposit size through the acquisition of the adjoining Mina Casiterita and Mina Hoyada properties, Eloro Resources may make for one of Bejet’s best bets yet.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

World(R) on January 26-29, 2023, unites a community of international enthusiasts devoted to podcasting technology and general communication with the world through the medium of audio and video.

Main stage sponsor SiriusXM will be represented at the 9th Annual Podfest Expo(R) 2023 supporting a community of creators whos’ origin began in 2013 as a meetup of 13 attendees. This year’s expo will be topping 1500+ Podcasters enjoying an immersive experience with over 200 Subject matter experts sharing their best practices

The venue of the event is Renaissance Orlando at SeaWorld(R) – within walking distance of SeaWorld(R) Orlando and the Aquatica water park, International Drive, and Orlando’s most celebrated attractions. Enjoy the spacious hotel accommodations with resort-style amenities, Netflix streaming services and inspiring views of SeaWorld(R), to make the Podfest experience memorable.

The event is curated for new as well as seasoned podcasters. The conference topics are easy to understand and customized as per a daily agenda based on what the attendees want to learn. Podfest has plenty to offer to all categories of podcasters who are willing to learn and share their best practices. The exhibitors will be showcasing the latest technology and services in the podcasting industry.

Hosting Podfests since 2015, this conference unites important speakers on a common platform to engage, discuss, and share valuable content with the worldwide Podfest community. The speakers are dignitaries, influencers, and thought leaders, who have profound knowledge in their niche fields.

Attendees can participate and gain knowledge on industry-crucial conference topics that are available in a fully customizable agenda that attendees can tailor per their interests, including:

• Creation and Launch
• Technology and Innovation
• Audience Growth
• Monetization and Marketing
• YouTube and Video
• Networking and Social

Some of the creators presenting at Podfest Expo(R) 2023 include Sara Dean of The Shameless Mom Academy; Kate Erickson of Kate’s Take; Innovation in Compliance with Tom Fox, Bryan Green of The Commercial Break, and Larry Roberts of Red Hat Media sharing how to use Chat GPT as a creator.

To learn more, please visit www.PodFestExpo.com and https://ibn.fm/U5ZEC.

Supply chain professionals and executives in the health and pharma spectrum are invited to attend the premiere Supplier Diversity & Economic Inclusion for Pharma & Healthcare Summit, streaming online on March 7-8th, 2023. Gain important insights and actionable strategies for strengthening supply chains by committing towards diversity, equity, and inclusion.

Supplier diversity is a relatively new term in supply chain management for pharma and healthcare. There is plenty of scope and need for market leaders who can streamline supplier diversity – including procurement, sourcing, regulatory, compliance, and other areas. Discover and overcome the most critical hurdles of working with small and diverse suppliers and gain actionable tips to consolidate and engage with supply partners and expand the supplier network on a global scale.

The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.

The event commences with the chairperson’s opening remarks followed by interactive discussion sessions on strengthening supplier diversity programs. Since finding the right supplier can be a daunting task, attendees will gain all-new insights on spending less time looking for suppliers and more time collaborating and engaging with them for effective results.

Participants will also learn about the procurement process and building capacity while understanding the process of scalability. These interactive sessions aid in overcoming misconceptions and implementing entirely different cultures to smooth out the supply chain process.

Post-lunch, experts will talk about building a strong pipeline of qualified supplier companies that can manage and operate robust supplier diversity programs.

Healthcare and pharma companies and executives can leverage this event forum to explore collaboration methods. They can learn novel strategies to engage with suppliers and apply them in their organization to drive business outcomes.

Supplier diversity programs can also aid in overcoming certification challenges. In addition, organizations can make the best use of these procurement strategies to engage with potential partners. Attendees will learn how to improve local diversity success for expanding reach globally while working to identify and partner with best-in-class diverse suppliers.

To learn more, please visit https://ibn.fm/b4soQ.

• Renewable textile innovator Coyuchi Inc. is dedicated to making luxury sustainable practice products a central part of the home living design industry
• Coyuchi’s President and CEO Eileen Mockus recently participated in a Bell2Bell podcast interview to discuss company achievements during 2022 and plans for 2023
• Coyuchi to introduce two new products in 2023 that will use cotton the company helped grow last year through a California farm focused on soil biodiversity and renewable practices
• The company’s Reg A+ investment offering, that was announced in August, already topped $1 million milestone in December

Organic luxury bed, bath, and apparel product innovator Coyuchi is celebrating the company’s new impetus for product category development and marketing thanks to enthusiasm for its Regulation A+ offering announced in August.

“One of the first use of funds that we kicked off at the end of 2022 was opening a second retail location here in Palo Alto, Calif. … That store launched just before all of the holiday selling kicked in along about mid-November and (we’re) still focusing on how do we enhance that customer experience,” company President and CEO Eileen Mockus said during a recent interview for InvestorBrandNetwork’s The Bell2Bell Podcast.

“Other things that we are working on, and we’ll have more of this coming in 2023, is looking at brand partnerships,” Mockus said. “We’re really interested in partnerships with other retailers. Seventy percent of bedding purchases are made through department stores. We’re an online business and we want to show up with other retailers.”

Those partnership goals include introducing Coyuchi’s lineup of sustainable living designs to the hospitality industry, she said.

Coyuchi has led the home industry in luxury organic textiles that have a small impact on the earth’s climate for over 30 years.

The company is pledging itself to achieve net zero emissions by 2025 and net positive emissions by 2030, and last year it announced the creation of a council of leaders with experience in the fashion, regenerative agriculture and sustainability industries to further realize its commitment.

“The complexities of the textiles supply chain do not allow for us to work alone, and when we launched our first circular product in 2020, we recognized the true value of our network in the battle against climate change,” Mockus stated at the time (https://ibn.fm/gRUeM).

As examples, Mockus noted the company’s collaboration with vendors who recycle the water in their textile processing operations and cotton growers who use renewable agriculture practices.

“(I’m) happy to share in 2022 (we) worked with a group called C4, which is the California Cotton and Climate Coalition, and grew some cotton on a farm in California, and had some great partners for that project … all looking for ways to increase biodiversity of the soil,” Mockus told Bell2Bell. “We took the cotton from that project and are launching two new products in 2023 that will use that cotton in the finished product from Coyuchi.”

Coyuchi’s original founder established the company’s goal to introduce organic cotton to the home goods sector of the textile industry, and the company has taken to heart its mission of using organic products that people will enjoy using at home, Mockus said.

The company’s net income grew 26 percent YOY between 2020 and 2021, according to an audited financial statement the company released earlier (https://ibn.fm/BitHG). The company indicated it had a return customer rate of 35 percent over 24 months, and Mockus said those returning customers were also a large part of the reason its Reg A+ offering was able to top the $1 million milestone by December 2022.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Homes contribute significantly to climate change, producing twice as much carbon dioxide emissions annually than automobiles
• GeoSolar Technologies’ SmartGreen(TM) Home system utilizes leading edge solar, geothermal and air filtration technology to offer true net zero homes that achieve some of the highest HERS index ratings in the industry
• The company recently published a webinar discussing the industry while providing comprehensive insight on SmartGreen(TM) homes, from financial to health

When it comes to greenhouse gases and carbon emissions that are polluting our atmosphere and contributing to climate change, cars are usually pointed at as the major culprit. That’s not an accurate accusation, though. As detailed by GeoSolar Technologies (“GST”) in a recent webinar available on YouTube, homes produce far more carbon dioxide than cars do and it’s not even close.

The average gasoline-powered car produces 4 tons of carbon dioxide annually. The average home doubles that, generating 8 tons of carbon dioxide each year.

After a decade of R&D, the team at GeoSolar Technologies has launched the SmartGreen(TM) home, a comprehensive makeover utilizing solar panels, geothermal, and electric heat pumps to generate clean, renewable energy to heat, cool, and power a home, albeit a new build or retrofit. The result is a house with no carbon emissions or utility bills with documented health benefits for the habitants. Houses today generally are 110+ on the 0-150 HERS(R) (Home Energy Ratings System) index, indicating highly inefficient. A SmartGreen(TM) home, as one of the most efficient, environmentally friendly homes available today, registers near 0.

GeoSolar refers to the installation process, which typically only takes a couple weeks from start to finish, as “DEP,” an acronym for decarbonization, electrification, and purification. During the modernization, the house’s shell is properly insulated, and any old, inefficient heating/cooling and non-electric components of a house are removed, replaced by solar panels on the roof, geothermal ground loops, electric heat pump, EV car charger, battery backup, and air filtration system.

With a SmartGreen(TM) home, there is no need for carbon monoxide detectors or all-house generators to protect against power outages. The electrical panel is replaced by what GeoSolar calls “SPAN,” a smart energy panel that provides a full picture of energy production and consumption.

As discussed by Dr. Ty Newell, owner of Build Equinox Smart Ventilation, the attention to air quality in a SmartGreen(TM) home distinguishes it from its peers. GeoSolar’s smart ventilation continuously monitors air quality and is highly effective against COVID-19, Valley Fever, and triggers for asthma, colds, flu, and allergies. This is particularly important considering the U.S. Environmental Protection Agency estimates that indoor pollutants are often 2-5 times higher than typical outdoor concentrations. According to Dr. Newell, the GeoSolar system puts “our health, comfort, and well-being at the forefront of the technology.” The entire system can be accessed and controlled through a smartphone.

Owing in part to drastically lower costs compared to a decade ago and growing awareness of need to transition away from fossil fuels, the home electrification trend is accelerating. The Inflation Reduction Act (“IRA”), passed into law late in 2022, should serve as a catalyst for the trend, considering incentives will cover about 40% of the cost for a homeowner to ditch natural gas, propane, or heating oil in favor of renewable energy. The IRA is leading a sea change that for the first time ever makes renewable energy for the home and vehicle less expensive than fossil fuel sources.

GeoSolar and its partners take care of the complete package for homeowners. They handle all the design, permitting, installation, commissioning, rebates, and financing to make the upgrades seamless with minimal disruption to the homeowner’s lives.

The GeoSolar team members walk the walk. Dar-Long Chan, PhD, is Director of New Product Development at GeoSolar. He left a 16-year career at Exxon where he learned in detail just how dirty fossil fuel energy is. Taking the approach to “lead fossil fuels before they lead me,” he made a personal and professional career change dedicated to clean energy transition, including moving into a SmartGreen(TM) net zero home in Colorado that uses about 25% of the energy of a traditional similar-sized house.

Stone Douglas, CEO at GeoSolar, is on a similar journey, decarbonizing and electrifying his house in California over a decade ago before it was becoming trendy. Douglas says that he made the transition purely for financial reasons and that was before all the robust incentives available today. He thinks with all the rebates and tax credits of the IRA, that homeowners can realize about a 7-year return on investment and then live without a utility bill, which he calls effectively a “tax-free dividend” of the investment made in your home, health, and environment.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly
• HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution
• “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO

With heart disease consistently being the leading cause of death in the United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution. HeartBeam’s efforts appear even more important looking forward. A recent Science Daily article (https://ibn.fm/xuLIq) reported that “by the year 2060, projected rates of cardiovascular risk factors and disease will increase significantly in the United States, according to a study published today in the Journal of the American College of Cardiology. Substantial increases in cardiovascular trends may contribute to a rising burden on the U.S. health care system and highlight the need for equitable access to prevention education and treatments now to prevent future disease.” Major cardiovascular (“CV”) risk factors include unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. “Among the general U.S. population, all four CV risk factors are expected to increase from 2025 to 2060,” the article continued. “The researchers found that stroke (33.8% to 15M) and heart failure (33.4% to 13M) were the highest projected increases in rates of cardiovascular diseases, followed by ischemic heart disease (30.7% to 29M) and heart attack (16.9% to 16M).” HeartBeam is focused on those rising heart attack numbers. The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack, and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. “Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” stated HeartBeam CEO and founder Branislav Vajdic, PhD (https://ibn.fm/XdfZO). “By providing remote, 12-lead 3D vector ECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting.” The company anticipates receiving regulatory approval soon for the use of the HeartBeam AIMI system in acute-care settings. In a recent report to shareholders, Vajdic noted that the company is in discussions with the FDA and expects the system to be cleared in Q1 2023. In an emergency situation, the software will provide an attending physician with an instant comparison of the patient’s baseline and symptomatic ECG along with diagnostic suggestions, enabling medical care providers to quickly determine if a patient needs intervention or can be discharged, which helps manage ED capacity. The company is planning to submit the first version of HeartBeam AIMIGo to the FDA in Q1 2023 as well. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• CubCrafters has acquired Summit Aircraft Skis, including the company’s design and manufacturing assets, unique patents, and related intellectual property
• The US Department of Agriculture Wildlife Service recently selected CubCrafters’ flagship FAA-certified CC19 XCub for a new government aircraft-fleet-modernization contract
• CubCrafters is now offering investment opportunities through a Regulation A+ offering – managed through Manhattan Street Capital

CubCrafters, a producer of best-in-class Backcountry Aircraft, announced its acquisition of Summit Aircraft Skis, including the company’s design and manufacturing assets, unique patents, and related intellectual property, from the Summit Aircraft Corporation of Sandpoint, Idaho, last month. Its unique design allows pilots to quickly and easily configure aircraft when flying in remote and primitive areas, which are otherwise inaccessible during winter months when runways are not maintained. Summit Aircraft Skis are favored by CubCrafters’ Carbon Cub aircraft owners and preferred by the owners of many other types of backcountry capable aircraft. Patrick Horgan, President and CEO of CubCrafters, said he was very pleased to welcome Summit’s customers and products into the CubCrafters family. “It has been a joy for our team to work together with Mike Custard, Summit’s founder, to coordinate a smooth ski manufacturing transition. Adding Summit Skis to the CubCrafters product lineup allows us to better meet our customers’ needs and adds a new profit center,” Horgan explained (https://ibn.fm/K086W). “We see great potential for growth with the Summit brand that we want to be a part of going forward.” CubCrafters designs and manufactures Experimental, LSA, and Part 23 Certified aircraft. The Carbon Cub family of aircraft has redefined how pilots experience backcountry flying through innovative design, modern materials, powerful engines, and breakthrough performance. The company’s flagship XCub aircraft is offered in both nosewheel and tailwheel configurations and substantially expands the profile for sport utility aircraft with higher speeds, longer ranges, and larger payloads possible. CubCrafters’ key to success is its ability to create unique value in the experience of adventure aviation. For nearly two decades, CubCrafters has supplied aircraft to various United States Federal Government agencies, including the US Air Force Research Laboratory, US Air Force Fight Academy, US Department of Agriculture, US Department of Homeland Security, and the US Department of the Interior. Federal civilian agencies use CubCrafters aircraft for aerial survey missions, natural resource management, patrol, surveillance, and search and rescue missions – including the US Air Force, which has tested various sensors and glider towing. The US Department of Agriculture Wildlife Service recently selected CubCrafters’ flagship FAA-certified CC19 XCub for a new government aircraft-fleet-modernization contract, which will extend the company’s long-term working relationship with the government. A recent article in General Aviation News quotes Horgan as saying that the new contract was very important for CubCrafters as a supplier for the US government, but also for investors participating in the company’s ongoing public offering (https://ibn.fm/Nc3l0). “This sale demonstrates that our newest generation of fully certified modern utility aircraft can replace the aging fleet of legacy aircraft now in service. It shows that there is a very bright future for our fleet sales program.” CubCrafters was recently qualified by the Securities and Exchange Commission to make a $50 million public stock offering to investors. For the first time in the 42-year history of CubCrafters, investors at all levels can purchase stock in the company through its Regulation A+ offering. Investments are being handled by Manhattan Street Capital. More information on the investment process can be found at https://ibn.fm/RdhfN. Note:  The 2023 CubCrafters calendar is ready to ship and is free to customers, fans, and general aviation enthusiasts. To order the 2023 CubCrafters calendar, visit https://ibn.fm/MeR10. For more information, visit the company’s website at www.CubCrafters.com. NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• Current monoclonal antibody therapies less effective against emerging COVID-19 variants
• BiondVax is developing an inhaled nanosized antibody (NanoAb) therapy for COVID-19 with human clinical Phase 1/2a results anticipated in 2023
• The global monoclonal antibodies market was valued at $185.5 billion in 2021 and is projected to grow at a CAGR of 11.3% due to the rising prevalence of chronic diseases and demand for biologics
• The biologics market size was valued at $366.5 billion in 2021 and is expected to reach $719.94 billion by 2030

According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some current vaccines and treatments less effective, which could results in a surge of breakthrough infections. To date, the BQ.1, BQ.1.1, XBB, and XBB.1 omicron subvariants are the most immune evasive variants of COVID-19 – causing 72% of new infections in the United States, according to data from the Centers for Disease Control and Prevention (https://ibn.fm/0n3vY). With scientists finding that these subvariants are “barely susceptible to neutralization” by vaccines, including the new omicron boosters, the immune response of people vaccinated and who had breakthrough infections with prior omicron variants are also weaker against subvariants (https://ibn.fm/fpdPg). The intended inhaled mechanism of delivery of BiondVax Pharmaceuticals’ (NASDAQ: BVXV) COVID-19 nanosized antibody (NanoAb) formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient, and likely safer for patients and providers. BiondVax recently reported data from a preclinical in vivo study indicating that compared to the control (placebo) group, hamsters treated with BiondVax’s inhaled NanoAb one day after infection had negligible (below detection level) SARS-COV-2 viral titers in their lungs, and experienced a milder and shorter illness in comparison to the placebo group that had average 30 times higher viral titers in their lungs at the end of the trial. BiondVax’s human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy is anticipated in 2023. NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization. The biologics market size was valued at $366.5 billion in 2021, and is expected to grow at a CAGR of 7.15%, reaching $719.94 billion by 2030. The approval of new biologic drugs is expected to further drive market growth during the forecast period and account for a significant share in 2021 (https://ibn.fm/90rgZ). BiondVax is focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. The company has an exclusive strategic collaboration with the Max Planck Society – the parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the University Medical Center Göttingen (“UMG”) for the development and commercialization of innovative NanoAb therapies starting with COVID-19. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative NanoAb pipeline. Since its inception, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of its prior influenza vaccine candidate. It has built a state-of-the-art manufacturing facility for biopharmaceutical products and is pursuing NanoAb therapies for additional disease indications with large market medical needs, such as asthma, psoriasis, macular degeneration, and psoriatic arthritis. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• In November 2018, Marriott suffered the loss of personal data for almost 383 million guests, highlighting the pitfalls and risks attached to businesses boasting an online profile
• Gartner revealed that 30% of enterprises would employ data security platforms by 2024, up from a mere 5% in 2019
• Data443 caters to the growing need for data discovery, governance, and protection services through its extensive and growing product suite – with services ranging from the data archiving and transfer through to ransomware recovery
• The company recently embarked on the next leg of its growth trajectory, recently raising over $1.5M with proceeds set to be devoted towards additional sales and marketing recruitment as well as the uplisting of the company on to the Nasdaq exchange
• Data443 also updated the market on the coveted VB100 certification which was recently awarded to its flagship Data443(R) Antivirus Protection Manager(TM)

In November 2018, hotel chain Marriott saw its worst fears realized; a massive data breach was detected within its systems with hackers stealing data belonging to as many as 383 million guests. Nearly four years in its gestation, the hack was reportedly alleged to have stolen a broad array of data including credit card and passport numbers, birth dates, phone numbers as well as hotel arrival and departure dates (https://ibn.fm/u0Vq1). Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company, has centered its mission around preventing the likes of the Marriott hack from ever being repeated, stating its steadfast commitment towards identifying and protecting all sensitive data regardless of location, platform, or format. A recent study by Gartner revealed that by 2024, over 30% of enterprises would have adopted data security platforms, up from less than 5% in 2019. Perhaps more importantly, the research firm’s study also showed how the majority of customers were focused on vender consolidation strategies – aiming to consolidate their various data security requirements from a single source. “The explosion of ransomware, zero-day attacks, third-party breaches, along with long-term remote work concerns & the integration of operational technology with IT systems have culminated into a crisis of confidence for IT security leaders” – IDG Security Priorities Study 2021 (https://ibn.fm/4dddk). Data443 continues to cater to the needs of an increasingly data security conscious corporate sector through its extensive product suite offering, one which boasted a range of solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. Some of the key elements included within its product suite included – data identification managers, designed to automatically catalog all data repositories; data placement manager, enabling the secure transfer of sensitive data across public and private networks; data archive manager, a purpose-built tool facilitating information archiving and retention; data hound, a data discovery, classification and capture toolset; as well as the ransom recovery manager, an industry leading solution which can assist users targeted by a hack to recover their device, operating systems and data with a simple reboot. Boasting over 10,000 customers in over 100 countries, Data443 has recently highlighted a series of new contract wins – among those, a new $350,000 contract with a leading global investment bank. The new contract will relate to additional licensing for the Data443 data placement manager product, an HPE NonStop server-based application for secure managed file transfer that enables customers to schedule, route, format, and securely transfer business-critical data over both public and private networks. Data443 founder and CEO Jason Remillard commented re the new contract win, “Today’s announcement is indicative of our continued efforts to provide world-class service and support to our critical customers. Data443’s Data Placement Manager(TM) has played a critical role at some of the largest fin tech firms in the world for over two decades, providing additional upsell opportunities for us to demonstrate our capabilities throughout the entire Data443 product suite. We believe that our highly reliable and capable software, being price competitive, and our vision for our technology stack all contributed to this win,” he concluded. Data443 has recently taken a series of measures designed to help fuel and cement its growth, with the company seeking to gain market share in a global data security market estimated to be worth over $54.23 billion by 2027, as per Allied Market Research. During December 2022, the company raised $750,000 in new capital, with the deal’s proceeds destined towards general corporate purposes, the recruitment of additional workers as well as a potential uplisting of the company to the Nasdaq Capital Markets in 2023 (https://ibn.fm/oo1gy). Finally, and coupled with the capital raising, Data443 also seized on the opportunity to reveal that its flagship antivirus product, Data443(R) Antivirus Protection Manager^™ had received its VB100 certification. A coveted designation administered by the industry’s leading reporting agency, Virus Billeting. The VB100 certification affirms that Data443’s antivirus product satisfies a broad array of criteria, including detecting all known-in-the-wild viruses, generating no false positives, and having the ability to perform both, scheduled and on-demand scans. With the designation putting Data443’s antivirus on an equal footing with some of the industry’s most lauded products, Jason Remillard reaffirmed his belief on Data443’s growth outlook going forward (https://ibn.fm/wHPIr). “At Data443, we make every effort to help protect customers from the ever-growing cyber threat environment. Achieving VB100 certification and besting some of the world’s largest competitors on false alarms delivers on our technical market leadership of our antivirus protection and ransomware product line. With so many antivirus products on the market, it can be difficult for consumers and businesses to determine which are truly effective at protecting against malware. VB100 certification helps to cut through the marketing hype and provides a reliable benchmark for comparing antivirus products,” he stated. For more information, visit the company’s website at www.Data443.com. NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS